Clinical trial
Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed…
NCT00237120 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00237120 |
|---|---|
| Title | Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase) |
| Official title | Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase) |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Myelogenous Leukemia in Chronic Phase |
| Intervention type | Drug |
| Interventions | Imatinib |
| Enrollment | 100 |
| Start date | Nov 1, 2002 |
| Completion | Jun 1, 2007 |
| First posted | Oct 12, 2005 |
| Last update posted | Nov 23, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: